€139.35
1.38%
L&S, Jun 28, 10:55 pm CET
ISIN
BE0003739530
Symbol
UCB
Sector
Industry

UCB Share price

€138.70
+11.45 9.00% 1M
+60.14 76.55% 6M
+59.80 75.79% YTD
+59.02 74.07% 1Y
+50.20 56.72% 3Y
+65.78 90.21% 5Y
+76.87 124.32% 10Y
Brüssel, Closing price Fri, Jun 28 2024
ISIN
BE0003739530
Symbol
UCB
Sector
Industry

Key figures

Market capitalization €26.32b
Enterprise Value €28.39b
PER (TTM) P/E ratio 76.55
EV/FCF (TTM) EV/FCF 74.91
EV/Sales (TTM) EV/Sales 5.41
P/S ratio (TTM) P/S ratio 5.01
P/B ratio (TTM) P/B ratio 2.93
Dividend yield 0.98%
Last dividend (FY24) €1.36
Sales growth (TTM) Sales growth -4.80%
Turnover (TTM) Turnover €5.25b
EBIT (operating result TTM) EBIT €655.00m
Free cash flow (TTM) Free cash flow €379.00m
EPS (TTM) EPS €1.81
P/E ratio expected 64.62
P/S ratio expected 4.68
EV/Sales expected 5.04
Show more

Is UCB a top scorer stock according to the dividend, high growth investing or Leverman strategy?

As a free StocksGuide basic user, you can view the scores for all 6,953 shares worldwide.

UCB Share analysis

Unlock scores for free

Analyst opinions

19 Analysts have issued a UCB forecast:

14x Buy
74%
5x Hold
26%

Analyst opinions

19 Analysts have issued a UCB forecast:

Buy
74%
Hold
26%

Financial data from UCB

Profit and loss account P&L | Balance sheet | Cash flow


TTM Annually
Dec '23
+/-
%
5,252 5,252
5% 5%
100%
- Direct costs 1,910 1,910
3% 3%
36%
3,342 3,342
9% 9%
64%
- Selling and administrative expenses 366 366
50% 50%
7%
- Research and development costs 1,630 1,630
2% 2%
31%
1,346 1,346
8% 8%
26%
- Depreciation and amortization 691 691
18% 18%
13%
EBIT (operating result) EBIT 655 655
1% 1%
12%
Net profit 343 343
18% 18%
7%

Figures in millions EUR.

Don't miss a thing! We will send you all news about the UCB share directly to your mailbox free of charge.

If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.

Company profile

UCB SA engages in the research, development, and commercialization of pharmaceutical and biotechnology products. It offers medicinal products such as briviact, keppra, vimpat, neupro, cimzia, nootropil, xyrem, xyzal, and zyrtec. The company was founded by Emmanuel Janssen on January 18, 1928 and is headquartered in Brussels, Belgium.

Head office Belgium
CEO Jean-Christophe Tellier
Employees 9,083
Founded 1925
Website www.ucb.com

Register for free

StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.

The Apple share at a glance with charts, current key figures, news and share analyses.
The best dividend stocks in the dividend top scorer list.
Stock analyses of the best stocks worldwide.
Build wealth now